Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

114 questions · 118 findings · 8 reviews

No studies found 14 · 11.9%GRADE not reported 20 · 16.9%Very low 48 · 40.7%Low 33 · 28%Moderate 3 · 2.5%High 0 · 0%

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Unacceptability of treatment (drop-outs / leaving study early) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Adverse effects (drop‐outs due to adverse effects4) · patients with schizophrenia

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to adverse effects (overall tolerability… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Desired sedation ‐ ultra short term ‐ tranquillised at 60 minutes · patients with schizophrenia

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS may leads to higher desired sedation ‐ ultra short term ‐ tranquillised at 60 minutes compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

Desired sedation ‐ ultra short term ‐ asleep at 12 hours · patients with schizophrenia

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS showed no clear difference in desired sedation ‐ ultra short term ‐ asleep at 12 hours compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

2 findings from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: drowsiness compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: dry mouth compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Adverse effects: spasmophilia · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: spasmophilia compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Adverse effects: euphoric behaviour · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: euphoric behaviour compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam) vs placebo

Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam) vs placebo

Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in taste compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clordemetildiazepam 1 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · clordemetildiazepam
    Bogetto 1999 (clordemetildiazepam) included in the benzodiazepine comparison but data not presented (79% placebo-arm attrition).
    1 study
    GRADE not reported